Olimestra (Olmesartan Medoxomil)

Olmesartan Medoxomil, the active ingredient in Olimestra, is an angiotensin II receptor blocker presented as a tablet for oral use. It treats hypertension and is indicated for adults who need blood pressure control.

GNH USA supplies Olimestra as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Olimestra is an angiotensin II receptor blocker used in the management of cardiovascular conditions that involve the renin‑angiotensin system. - Hypertension: lowers systolic and diastolic blood pressure to reduce cardiovascular risk. - Heart failure: used as part of combination therapy to improve symptoms and outcomes. - Diabetic nephropathy: helps slow progression of kidney damage associated with type 2 diabetes.

Adverse reactions to olmesartan are reported across a spectrum of frequency.

Common Side Effects: - Dizziness or light‑headedness - Headache - Fatigue - Nasal congestion - Diarrhoea - Upper respiratory tract infection

Serious or Rare Side Effects: - Angio‑edema involving the face, lips or tongue - Severe hypotension - Acute kidney injury - Hyperkalemia - Liver enzyme elevation - Bullous pemphigoid skin disorder

Olimestra should be used with clinical oversight and patient‑specific risk assessment. - Renal impairment: dose may need adjustment and renal function monitored. - Hepatic impairment: use with caution; monitor liver enzymes. - Electrolyte disturbances: watch for hyperkalaemia, especially with potassium‑sparing diuretics. - Pregnancy: contraindicated in the second and third trimesters; avoid use. - Concomitant NSAID therapy: may increase risk of renal dysfunction. - Store at ambient temperature: keep in the original container, protect from moisture and light.

Olmesartan can interact with several drug classes, requiring vigilance from prescribers.

Major Interactions (Avoid): - Dual renin‑angiotensin system blockade (e.g., ACE inhibitor or another ARB): risk of severe hypotension, hyperkalaemia and renal failure. - Potassium‑sparing diuretics or supplements: heightened risk of hyperkalaemia.

Moderate Interactions (Monitor Closely): - Non‑steroidal anti‑inflammatory drugs (NSAIDs): may impair renal function and blunt antihypertensive effect. - Lithium: can increase serum lithium levels, risking toxicity. - Cyclosporine or tacrolimus: may raise olmesartan concentrations and affect kidney function. - Diuretics (thiazide or loop): may enhance antihypertensive effect, requiring blood pressure monitoring.